Skip to main content
Clinical Trials/NL-OMON48911
NL-OMON48911
Completed
Not Applicable

A single-center, randomized, double-blind, placebo-controlled, parallel-group studie investigating the safety, tolerability and pharmacokinetics of single- and multiple-ascending subcutaneous doses of TA-46 in healthy volunteers - TA-46 SAD and MAD dose study to investigate safety and PK

Therachon SAS0 sites102 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Achondroplasia
Sponsor
Therachon SAS
Enrollment
102
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • \- healthy male or female subjects
  • \- female volunteers sterilized or post\-memopausal
  • \- 21\-55 yrs, inclusive
  • \- BMI: 18\.0\-28\.0 kg/m2, inclusive
  • \- non\-smoking or light smokers (smoking not allowed in clinic)

Exclusion Criteria

  • Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of
  • participation in another drug study within 90 days before the start of this
  • study or being a blood donor within 60 days from the start of the study. In
  • case of donating more than 1\.5 liters of blood in the 10 months prior the start
  • of this study.

Outcomes

Primary Outcomes

Not specified

Similar Trials